DASH Trial
Start date:June 2019
Why?
Medications to ‘thin’ the blood can have an unwanted effect on strokes caused by bleeding in the brain. Controlling bleeding is crucial in the first few hours after stroke but there is still uncertainty over the best course of treatment.
What?
DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.
Research Team
Allan MacRaild
Stroke Lead Research Nurse
Seona Burgess
Senior Stroke Research Nurse
Pat Taylor
Senior Stroke Research Nurse
Rachel O'Brien
Lead Research Nurse
Julia Grahamslaw
Lead Research Nurse
Fiona McCurrach
Senior Research Nurse
More EMERGE Trials
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
NOVEL Study
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.
TARGET-CTCA Trial
ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study
ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)